3.5 Bronchiectasis and Cystic Fibrosis

Key Takeaways

  • Suspect bronchiectasis with persistent productive or wet cough and recurrent infection. Confirm a compatible clinical syndrome with age-appropriate chest CT and investigate underlying causes.

  • Teach airway clearance and use sputum results and severity to guide exacerbation treatment. Specialist prevention options depend on exacerbation history and microbiology.

  • An abnormal Irish newborn bloodspot screen for cystic fibrosis requires specialist diagnostic assessment. Characteristic symptoms also merit assessment after a negative screen.

  • Cystic fibrosis care links airway clearance and infection surveillance with nutrition, pancreatic function, complication monitoring and genotype-directed treatment.

Last updated: November 2026

Recognise bronchiectasis and investigate its cause

Chronic airway inflammation and impaired mucus clearance reinforce each other. Damaged, dilated bronchi retain secretions, which support infection and further inflammation. A persistent productive cough, recurrent antibiotic-treated chest infections and intermittent haemoptysis should raise suspicion. Assess oxygenation and the amount of bleeding during an acute presentation. Major haemoptysis or respiratory compromise needs emergency escalation while the underlying cause is investigated.

DecisionAdultChild or adolescent
Recognise the patternDaily sputum between infections, repeated exacerbations or prior growth of an organism such as Pseudomonas supports further investigation. Asthma or COPD may coexist.Persistent or recurrent wet cough, recurrent pneumonia or failure to improve with appropriate treatment for protracted bacterial bronchitis warrants paediatric respiratory assessment.
Confirm the diagnosisThin-section chest CT shows abnormally dilated bronchi. Failure of tapering and peripheral visible bronchi also support the diagnosis in the right clinical setting.Use paediatric CT criteria and specialist interpretation. Airways and adjacent vessels have different normal proportions in children.
Identify a treatable causeCheck sputum microbiology, including mycobacterial cultures, serum immunoglobulins and allergic bronchopulmonary aspergillosis testing. Use history to guide evaluation for cystic fibrosis, primary ciliary dyskinesia, aspiration, immune disease or focal obstruction.Investigate causes early. The ERS minimum panel includes a sweat test, immune studies and lower-airway bacteriology where available, with spirometry when feasible. Persistent focal findings can prompt evaluation for an inhaled foreign body.

Worked application

A 47-year-old has daily purulent sputum even between three antibiotic-treated infections in the past year. CT shows bilateral dilated bronchi without normal tapering, and previous spirometry showed persistent airflow obstruction. The clinical syndrome and CT support bronchiectasis. Review the obstructive pattern separately, collect respiratory samples and investigate causes. This patient needs physiotherapist-taught airway clearance and an assessment of the cause of repeated exacerbations. Simply escalating inhalers leaves the mucus clearance problem and possible chronic airway infection untreated.

ERS adult bronchiectasis guideline, 2025 · ERS child and adolescent bronchiectasis guideline, 2021

Treat exacerbations and reduce recurrence

  1. Assess a change from baseline. Worsening cough, greater sputum volume or purulence, breathlessness, fatigue or haemoptysis can signal an exacerbation. Check for pneumonia, sepsis and acute respiratory failure when the presentation warrants it. Obtain sputum before antibiotics when practical and use previous cultures and local antimicrobial guidance to select initial treatment.
  2. Review response and adjust. ERS adult guidance typically uses 14 days for severe exacerbations or Pseudomonas infection. A shorter course may be appropriate in selected adults with a rapid response. The paediatric ERS guideline recommends 14 days. Significant hypoxia, deterioration or failure of an appropriate oral regimen calls for urgent reassessment and consideration of admission and IV treatment.
  3. Build a prevention plan. A respiratory physiotherapist teaches an individual airway clearance technique and reviews it as symptoms change. Assess exercise limitation and consider pulmonary rehabilitation in adults where indicated. Review vaccination, smoking exposure and management of underlying causes.
  4. Act on microbiology and exacerbation risk. A new Pseudomonas isolate can prompt a specialist discussion about eradication. Chronic Pseudomonas with a high exacerbation risk can warrant long-term inhaled antibiotics. Before a long-term macrolide, review microbiology for nontuberculous mycobacteria, QT risk, interactions, liver function and hearing. Macrolide monotherapy can select resistance when active nontuberculous mycobacterial disease is present.

Brensocatib is an EU-authorised specialist option for non-CF bronchiectasis from age 12 with at least two exacerbations in the previous 12 months. Continue to address airway clearance and individual microbiology when considering preventive treatment.

ERS adult guideline · HSE adult respiratory azithromycin guidance · EMA brensocatib indication

Follow cystic fibrosis from suspicion to confirmed diagnosis

Cystic fibrosis is an autosomal recessive disorder of CFTR ion transport. Dehydrated airway secretions impair clearance. Pancreatic duct obstruction can produce exocrine insufficiency, steatorrhoea and poor growth. Other clues include meconium ileus, persistent wet cough, recurrent infections, or bronchiectasis with chronic sinus disease. The age and combination of findings vary. Some patients retain pancreatic function.

The Irish newborn bloodspot programme screens for cystic fibrosis and refers infants who need further assessment. A screen result estimates risk. The CF team uses sweat chloride, CFTR genetics and other testing when required to establish whether CFTR dysfunction is present. Investigate a compatible later presentation even after a negative screen.

Sweat chloride in a properly collected sampleInterpretation in the diagnostic pathway
Below 30 mmol/LCF is unlikely, but strong clinical or genetic evidence can justify further assessment.
30–59 mmol/LIntermediate. Arrange repeat testing and specialist interpretation with genotype and clinical findings. An infant with an inconclusive diagnosis needs planned follow-up.
At least 60 mmol/LSupports a CF diagnosis with a positive newborn screen, relevant symptoms or a family history. The specialist team confirms the result through the diagnostic pathway.

Coordinate long-term care with the CF team

Follow respiratory symptoms, spirometry when feasible and airway cultures. Teach and review airway clearance. Prevent cross-infection and select exacerbation therapy using prior isolates and the specialist plan. Inhaled therapies such as dornase alfa or hypertonic saline are options in CF under that plan. Recombinant DNase should be avoided as routine treatment for adult non-CF bronchiectasis.

Assess pancreatic function, growth and nutritional status. Pancreatic enzyme replacement with meals and snacks treats pancreatic insufficiency. The team monitors fat-soluble vitamins, salt and nutritional needs, and screens for complications such as CF-related diabetes, liver disease and reduced bone health. Discuss inheritance and family testing with the CF team. CFTR modulators depend on age and the CFTR variant. For example, the EU Kaftrio label in combination with ivacaftor covers eligible patients aged 2 years and older with at least one non-class I CFTR mutation, with formulation selected by age.

HSE newborn bloodspot screening · CF Foundation diagnostic consensus · European CF standards of care · EMA Kaftrio indication

Test Your Knowledge

A 62-year-old with CT-confirmed non-CF bronchiectasis has a fourth exacerbation in 12 months despite regular airway clearance. Two previous sputum cultures and the current sample grew Pseudomonas aeruginosa. The acute exacerbation is already being treated. Which strategy should the respiratory team now assess for prevention?

A

A course of eradication treatment for a first Pseudomonas isolate

B

Long-term inhaled antibiotic treatment for chronic Pseudomonas infection

C

Daily dornase alfa to reduce future exacerbations

D

Long-term azithromycin started before reviewing mycobacterial cultures or the ECG

Test Your Knowledge

A thriving 5-week-old infant is referred after a positive Irish newborn bloodspot screen for cystic fibrosis. Sweat chloride is 44 mmol/L from an adequate sample. What is the appropriate diagnostic plan?

A

Discharge to routine care because the infant is gaining weight

B

Confirm cystic fibrosis from the bloodspot and the first sweat chloride result

C

Repeat sweat chloride and review CFTR testing through the specialist CF team

D

Use faecal elastase as the deciding test and discharge if it is normal

Sections you finish are checked off in the contents.